<DOC>
	<DOCNO>NCT01590641</DOCNO>
	<brief_summary>Dose cohort may dose one 4 possible total weekly dos ( 0.3 mg , 1 mg , 2 mg , 4 mg ) . Dose escalation repetition govern pre-specified safety activity rule . Subjects confine either day 1-3 day 1-3 8-10 . Follow-up visit also require periodically day 43 , potential viral load follow-up visit week 3 6 month post last dose . Study procedures involve blood draw pharmacokinetic , pharmacodynamic , virologic , safety assessment</brief_summary>
	<brief_title>A Study Evaluating GS-9620 Treatment Naive Subjects With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Chronic HBV infection ≥ 6 month HBsAg ≥ 250 IU/mL HBV treatment naïve Absence extensive bridging fibrosis ( Metavir 3 great ) cirrhosis Creatinine clearance ≥ 70 mL/min Coinfection hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV History Gilberts disease Laboratory parameter within defined threshold leukopenia , neutropenia , anemia , thrombocytopenia , thyroidstimulating hormone ( TSH ) , evidence hepatic decompensation Diagnosis autoimmune disease , poorly control diabetes mellitus , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , malignancy , hemoglobinopathy , retinal disease , patient immunosuppressed Evidence hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>HBV</keyword>
	<keyword>GS-9620</keyword>
	<keyword>Toll-like receptor ( TLR ) -7 Agonist</keyword>
</DOC>